安罗替尼联合注射用紫杉醇(白蛋白结合型)二线治疗晚期驱动基因阴性NSCLC患者的效果

Effect of Anlotinib Combined with Paclitaxel for Injection(Albumin Bound)in the Second-line Treatment of Patients with Advanced Driver Gene Negative NSCLC

目的:探讨安罗替尼联合注射用紫杉醇(白蛋白结合型)二线治疗晚期驱动基因阴性非小细胞肺癌(NSCLC)患者的效果。方法:将张家港市第一人民医院2019年2月-2021年9月收治的68例晚期驱动基因阴性NSCLC患者按照随机数字表法分为联合组和单药组,各34例。单药组予以紫杉醇(白蛋白结合型)治疗,联合组在单药组基础上予以安罗替尼治疗,观察两组的临床疗效、生存质量、生存状况及不良反应发生情况。结果:联合组疾病控制率为85.29%,高于单药组的61.76%(P<0.05);联合组的社会/家庭、情感、功能得分高于单药组,联合组生理、附加关注状况得分低于单药组,差异均有统计学意义(P<0.05);联合组6个月内无进展生存率为58.82%,高于单药组的32.35%(P<0.05);联合组各类不良反应发生率与单药组对比差异无统计学意义(P>0.05)。结论:将安罗替尼与紫杉醇(白蛋白结合型)联合用于晚期驱动基因阴性NSCLC患者的二线治疗中,有助于提高疾病控制率,改善生存质量,增加无进展生存率,且不增加不良反应发生率。

Objective:To investigate the effect of Anlotinib combined with Paclitaxel for Injection(Albumin Bound)in the second-line treatment of patients with advanced driver gene negative non-small cell lung cancer(NSCLC).Method:A total of 68 patients with advanced driver gene negative NSCLC who were admitted to Zhangjiagang First People’s Hospital from February 2019 to September 2021 were divided into combination group and single drug group according to the random number table method,34 cases in each group.The single drug group was treated with Paclitaxel for Injection(Albumin Bound),and the combination group was treated with Anlotinib on the basis of the single drug group.The clinical efficacy,quality of life,survival status and adverse reactions were observed in the two groups.Result:The disease control rate in the combination group was 85.29%,which was higher than 61.76%in the single drug group(P<0.05).The social/family,emotional and function scores in the combination group were higher than those in the single drug group,and the scores of physiological and additional concerns in the combination group were lower than those in the single drug group,the differences were statistically significant(P<0.05).The progression free survival rate within 6 months in the combination group was 58.82%,which was higher than 32.35%in the single drug group(P<0.05).There were no significant differences in the incidence of various adverse reactions between the two groups(P>0.05).Conclusion:The combination of Anlotinib and Paclitaxel for Injection(Albumin Bound)in the second-line treatment of advanced driver gene negative NSCLC patients can help to improve the disease control rate,improve the quality of life,increase the progression-free survival rate,and not increase the incidence of adverse reactions.